STOCK TITAN

InspireMD prices offering for about $37.5M gross

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

InspireMD, Inc. (NSPR) priced an underwritten public offering with estimated gross proceeds of approximately $37.5 million, or approximately $43.1 million if the underwriters exercise a 30-day option in full. The company is selling 7,342,308 common shares and pre-funded warrants to purchase up to 50,350,000 shares, accompanied by warrants to purchase up to 43,269,231 shares. The combined price is $0.65 for each common share and accompanying warrant, and $0.6499 for each pre-funded warrant and accompanying warrant.

Closing is expected on or about November 16, 2026, subject to customary conditions. InspireMD intends to use net proceeds for research and development, sales and marketing, working capital and general corporate purposes. The underwriters receive a 6.0% discount on gross proceeds. Pre-funded warrants are immediately exercisable at $0.0001 per share; common warrants are immediately exercisable at $0.65 and expire one year after issuance. A holder, its affiliates and attribution parties may not exercise to the extent that post-exercise beneficial ownership would exceed 4.99%, or 9.99% if elected. The company also cites recurring losses, negative operating cash flows and substantial doubt about its ability to continue as a going concern.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointInspireMD reports substantial doubt about its ability to continue as a going concern.

Filing Explained

Under the November 13, 2026 underwriting agreement, InspireMD agreed not to issue or sell common shares or securities convertible into or exercisable for them until 60 days after closing, or enter variable-rate transactions until six months after closing, without the representative’s written consent. Its officers and directors separately agreed not to sell or transfer covered securities for 60 days from the agreement date.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Estimated gross proceeds Approximately $37.5 million Before underwriting discounts, commissions and estimated offering expenses; excludes proceeds, if any, from warrant exercises.
Estimated gross proceeds with option exercised in full Approximately $43.1 million Estimate if the underwriters exercise the option to purchase additional securities in full.
Common shares offered 7,342,308 shares Shares in the underwritten public offering.
Shares underlying pre-funded warrants Up to 50,350,000 shares Shares the pre-funded warrants may purchase.
Shares underlying common warrants Up to 43,269,231 shares Shares the accompanying common warrants may purchase.
Combined public offering price $0.65 Per common share and accompanying common warrant.
Combined public offering price $0.6499 Per pre-funded warrant and accompanying common warrant.
Underwriting discount 6.0% Percentage of gross proceeds payable to the underwriters.
Pre-Funded Warrants financial
"Each Pre-Funded Warrant has an exercise price of $0.0001 per share"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
over-allotment financial
"solely to cover over-allotment, if any"
An over-allotment is an arrangement that lets underwriters sell a small, predefined extra amount of shares beyond an initial offering to meet unexpected demand and smooth trading, like a bakery baking a few extra loaves for a sudden rush of customers. It matters to investors because it temporarily increases supply, can reduce price swings by allowing underwriters to buy back shares if the price falls, and may cause modest, planned dilution if those extra shares are retained.
underwriting discount financial
"an underwriting discount equal to 6.0% of the gross proceeds"
The underwriting discount is the fee that investment banks or broker-dealers keep when they buy securities from an issuer and resell them to the public; it’s the difference between the price paid to the company and the public offering price, shown per share or as a percentage. It matters to investors because it reduces the cash the company actually raises and is a cost built into the deal—like a sales commission—so a larger discount can mean higher issuance costs, tighter returns for new investors, and a signal about how much effort underwriters must expend to sell the offering.
shelf registration statement regulatory
"effective shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
beneficially own regulatory
"would beneficially own more than 4.99%"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
variable rate transactions financial
"not to effect or enter into any variable rate transactions"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is InspireMD’s (NSPR) offering expected to raise?

InspireMD estimates gross proceeds of approximately $37.5 million before underwriting discounts, commissions and estimated company-paid offering expenses, excluding any proceeds from warrant exercises. If the underwriters exercise their option to purchase additional securities in full, gross proceeds are estimated at approximately $43.1 million.

What are the exercise terms for InspireMD’s (NSPR) warrants?

Pre-funded warrants are immediately exercisable at $0.0001 per share. Common warrants are immediately exercisable at $0.65 per share and expire one year from issuance. A holder, its affiliates and attribution parties may not exercise if doing so would result in beneficial ownership above 4.99%, or 9.99% if elected.

When is InspireMD’s (NSPR) offering expected to close?

The offering is expected to close on or about November 16, 2026, subject to satisfaction or waiver of customary closing conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001433607 0001433607 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): November 13, 2026

 

InspireMD, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35731   26-2123838
(Commission
File Number)
  (IRS Employer
Identification No.)

 

6303 Waterford District Drive, Suite 215
Miami, Florida
  33126
(Address of Principal Executive Offices)   (Zip Code)

 

(888) 776-6804

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   NSPR   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On November 13, 2026, InspireMD, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “Offering”) of (i) 7,342,308 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and pre-funded warrants to purchase up to 50,350,000 shares of Common Stock (the “Pre-Funded Warrants”), and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of Common Stock (or, at the election of the holder, pre-funded warrants to purchase up to an equal number of shares of Common Stock in lieu thereof) (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”), representing 75% of the aggregate number of Shares and Pre-Funded Warrants sold in the Offering. Each Share is being sold together with an accompanying Common Warrant at a combined public offering price of $0.65, and each Pre-Funded Warrant is being sold together with an accompanying Common Warrant at a combined public offering price of $0.6499, which equals the combined public offering price per Share and accompanying Common Warrant, minus $0.0001.

 

Pursuant to the Underwriting Agreement, the Company has agreed to pay the Underwriters an underwriting discount equal to 6.0% of the gross proceeds of the Offering. All of the securities in the Offering are being sold by the Company. Pursuant to the Underwriting Agreement, the Company also agreed to reimburse the Representative for certain expenses up to $125,000.

 

The Underwriting Agreement contains customary representations, warranties and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties. Pursuant to the Underwriting Agreement, and subject to certain exceptions, the Company has agreed not to issue or sell any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock for a period beginning on the date of the Underwriting Agreement and ending 60 days following the closing of the Offering, and not to effect or enter into any variable rate transactions for a period beginning on the date of the Underwriting Agreement and ending six months following the closing of the Offering, in each case without the prior written consent of the Representative. In addition, the Company’s executive officers and directors have agreed, subject to certain exceptions, not to sell or transfer any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock for a period of 60 days from the date of the Underwriting Agreement without the prior written consent of the Representative.

 

The Company also granted the Representative a 30-day option to purchase up to 8,653,846 additional shares of Common Stock and/or Pre-Funded Warrants to purchase up to 8,653,846 shares of Common Stock and/or Common Warrants to purchase up to 6,490,384 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) (or any combination thereof) at the applicable public offering price minus underwriting discounts and commissions, representing 15% of the total number of shares of Common Stock, Pre-Funded Warrants and Common Warrants sold in the Offering, solely to cover over-allotment, if any.

 

Each Pre-Funded Warrant has an exercise price of $0.0001 per share of Common Stock, is immediately exercisable upon issuance and may be exercised at any time until exercised in full. Each Common Warrant has an exercise price of $0.65 per share of Common Stock, is immediately exercisable upon issuance, will expire one year from the date of issuance and may be exercised, at the holder’s election, for Pre-Funded Warrants in lieu of shares of Common Stock. A holder may not exercise any portion of its Warrants to the extent that the holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding Common Stock immediately after exercise.

 

The Common Warrants will be issued pursuant to a warrant agency agreement, dated as of November 12, 2026 (the “Warrant Agency Agreement”), by and between the Company and Securities Transfer Corporation, as warrant agent.

 

The Company estimates that the gross proceeds of the Offering will be approximately $37.5 million (or approximately $43.1 million if the Representative exercises its option to purchase additional securities in full), prior to deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Warrants. The Company intends to use the net proceeds from the Offering for the Company’s operations, including, but not limited to, research and development, sales and marketing, working capital and other general corporate purposes.

 

 

 

 

The closing of the Offering is expected to occur on or about November 16, 2026, subject to the satisfaction or waiver of customary closing conditions.

 

The Offering is being made pursuant to the Company’s effective shelf registration statement on Form S-3 (No. 333-286309), filed with the Securities and Exchange Commission (“SEC”) on April 1, 2025, which became effective on April 10, 2025, and the base prospectus included therein (the “Registration Statement”), as supplemented by preliminary prospectus supplement, dated November 12, 2026, which was filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), and a final prospectus supplement, dated November 13, 2026, relating to and describing the terms of the Offering will be filed with the SEC pursuant to Rule 424(b) under the Securities Act on November 16, 2026.

 

The Underwriting Agreement, the form of Pre-Funded Warrant, the form of Common Warrant and the Warrant Agency Agreement are filed as Exhibits 1.1, 4.1, 4.2 and 4.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The foregoing descriptions of the terms of the Underwriting Agreement, the Pre-Funded Warrants, the Common Warrants and the Warrant Agency Agreement are qualified in their entirety by reference to such exhibits.

 

A copy of the opinion, including the related consent, of Greenberg Traurig, P.A. relating to the legality of the issuance and sale of the securities in the Offering is filed as Exhibit 5.1 hereto.

 

Item 8.01 Other Events.

 

On November 13, 2026, the Company issued a press release to announce the pricing of the Offering (the “Pricing Press Release”). A copy of the Pricing Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 

 

 

Forward Looking Statements

 

This Current Report on Form 8-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, this Current Report on Form 8-K states that the Offering is expected to close on or about November 16, 2026. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary in underwritten public offerings in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offering may not close. In addition, forward looking statements in this Current Report on Form 8-K also include the intended use of proceeds from the Offering. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Current Report.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number   Description
1.1   Underwriting Agreement, dated November 13, 2026, by and between InspireMD, Inc. and Lake Street Capital Markets, LLC, as representative of the several underwriters named therein
4.1   Form of Pre-Funded Warrant to Purchase Common Stock
4.2   Form of Series L Warrant to Purchase Common Stock
4.3   Warrant Agency Agreement, dated November 12, 2026, by and between InspireMD, Inc. and Securities Transfer Corporation
5.1   Opinion of Greenberg Traurig, P.A.
23.1   Consent of Greenberg Traurig, P.A. (included in Exhibit 5.1)
99.1   Pricing Press Release, dated November 13, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INSPIREMD, INC.
   
Date: November 16, 2026 By: /s/ Marvin Slosman
  Name: Marvin Slosman
  Title: Chief Executive Officer

 

 

 

Exhibit 99.1

 

InspireMD Announces Pricing of $37.5 Million Public Offering

 

Miami, FL -- November 13, 2026 — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing of its previously announced underwritten public offering of (i) 7,342,308 shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase 50,350,000 shares of its common stock, and (iii) accompanying common warrants to purchase 43,269,231 shares of its common stock (or pre-funded warrants in lieu thereof). All securities in the offering are being offered by InspireMD.

 

In addition, the Company granted the underwriters a 30-day option to purchase additional 8,653,846 shares of the Company’s common stock and/or 8,653,846 pre-funded warrants and/or additional common stock warrants to purchase 6,490,384 shares of common stock (or pre-funded warrants in lieu thereof) (or any combination thereof), representing 15% of the total number of shares of common stock and pre-funded warrants sold in the offering, solely to cover over-allotments, if any.

 

The offering is expected to close on or about November 16, 2026, subject to satisfaction of customary closing conditions.

 

Lake Street Capital Markets is acting as the sole book runner for the offering.

 

InspireMD intends to use the net proceeds from the offering, if any, for research and development, sales and marketing, working capital and other general corporate purposes.

 

The securities are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-286309) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2025, and declared effective by the SEC on April 10, 2025. A preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC on November 12, 2026. Copies of the final prospectus supplement and accompanying base prospectus will be filed with the SEC and, when available, may be obtained free of charge at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the offering may be obtained from Lake Street Capital Markets, LLC at 121 South Eighth Street, Suite 1000, Minneapolis, MN 55402, or e-mail at prospectus@lakestreetcm.com.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

 

About InspireMD, Inc.

 

InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.

 

 

 

 

 

 

Forward-looking Statements

 

This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. These forward-looking statements include, but are not limited to, statements regarding the closing of the offering and the anticipated use of proceeds.

 

In particular, forward-looking statements in this press release include the Company’s expectations regarding the public offering, including its anticipated completion, and the intended use of proceeds from the offering. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.

 

Such risks and uncertainties include, without limitation, risks associated with the public offering, including market conditions, the possibility that the offering may not be completed on the anticipated terms or at all, and the Company’s ability to deploy any proceeds from the offering as intended; risks and uncertainties associated with the voluntary U.S. recall of the CGuard Prime 135 cm delivery system, including current and future costs associated with the recall, including refunds or inventory write-off costs and other remediation costs, loss of sales and customers due to the recall or otherwise, our ability to effectively implement enhancements to CGuard Prime 135 cm delivery system, potential actions by regulators or other governmental entities associated with the recall, potential claims and lawsuits by customers and patients, including class action product liability lawsuits, other operational impacts and consequences of the recall, such as business disruption and distraction of management and other key employees; the Company’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of its liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; the Company’s need to raise additional capital to meet its business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders’ ownership interests; the clinical development, commercialization and market acceptance of the Company’s products; whether the clinical trial results for the Company’s products will be predictive of real-world results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; negative clinical trial results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing standards; the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercial launch of its products; the Company’s dependence on a single manufacturing facility and its ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an attractive alternative to other procedures and products; intense competition in the Company’s industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than it does; entry of new competitors and products and potential technological obsolescence of the Company’s products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with the Company’s research and products and potential product liability claims; product malfunctions; price increases for supplies and components; whether access to the Company’s products is achieved in a commercially viable manner and whether its products receive adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully obtain and maintain intellectual property protection covering its products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that the Company conducts business in multiple foreign jurisdictions, exposing it to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; security, political and economic instability in the Middle East that could harm the Company’s business, including due to the current security situation in Israel; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on the Company, its customers and suppliers, and the global economic environment.

 

More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

Investor Contact

 

Investor Contacts:

 

Jeff Warren

LifeSci Advisors

jwarren@lifesciadvisors.com

investor-relations@inspiremd.com

 

 

 

Filing Exhibits & Attachments

11 documents

Keep reading